Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia
An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning ...
Cancer
Dec 24, 2012 |
5 / 5 (1) |
0
|
Drug targets hard-to-reach leukemia stem cells responsible for relapses
Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms ...
Cancer
Jan 17, 2013 |
3.7 / 5 (3) |
0
|
BIM gene variation in East Asians found to explain resistance to cancer drugs
A multi-national research team led by scientists at Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs.
Cancer
Mar 18, 2012 |
not rated yet |
0
|
Therapy targets leukemia stem cells
New research takes aim at stubborn cancer stem cells that are thought to be responsible for treatment resistance and relapse. The study, published by Cell Press in the February 14 issue of the journal Cancer Cell, provid ...
Cancer
Feb 13, 2012 |
4 / 5 (4) |
0
Researchers identify possible new oncogene and future therapy target
A gene that may possibly belong to an entire new family of oncogenes has been linked by researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) to the resistance ...
Cancer
Sep 11, 2012 |
5 / 5 (1) |
0
|
The link between TB and a gene mutation that causes lung cancer
Tuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease ...
Cancer
Jan 18, 2012 |
not rated yet |
0
Jak of all trades? Not of leukaemia therapy
About one in five or six cases of adult leukaemia in Western populations relates to so-called chronic myeloid leukaemia, or CML. Treatment of CML usually relies on inhibitors of the abnormal protein that causes the condition ...
Cancer
Jan 30, 2012 |
not rated yet |
0
Combination therapies for drug-resistant cancers
Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts ...
Cancer
Oct 10, 2011 |
5 / 5 (1) |
0
A genetic variation common in East Asian populations has been linked to cancer drug resistance
Tyrosine kinase inhibitors (TKIs) kill cancerous cells by inducing programmed cell death. They are of enormous therapeutic benefit to patients with chronic myeloid leukemia (CML) and certain types of lung ...
Genetics
Aug 02, 2012 |
not rated yet |
0
Multi-tasking imatinib boosts radiotherapy for bladder tumours
Cancer drug imatinib (Glivec) could boost radiotherapy treatment to destroy bladder cancer that has spread to the bladder wall, reveals research published in Cancer Research.
Cancer
Mar 04, 2013 |
not rated yet |
0
Double whammy: RNAi enhances lung cancer therapy
Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is usually treated with surgery and chemotherapy. However, a small group of patients can also be helped by treatment with tyrosine kinase inhibitors ...
Cancer
Mar 20, 2012 |
not rated yet |
0
Leukemia drug reverses tamoxifen-resistance in breast cancer cells
Taking a leukemia chemotherapy drug may help breast cancer patients who don't respond to tamoxifen overcome resistance to the widely-used drug, new research from the Kimmel Cancer Center at Jefferson suggests. ...
Cancer
Aug 01, 2011 |
not rated yet |
0
|
Leading leukemia experts: High leukemia treatment costs may be harming patients
The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according ...
Cancer
Apr 25, 2013 |
not rated yet |
0
Cabozantinib active in castration-resistant prostate cancer
(HealthDay)—The orally bioavailable tyrosine kinase inhibitor cabozantinib (XL184) has clinical activity in men with castration-resistant prostate cancer (CRPC), according to a study published online Nov. ...
Cancer
Dec 03, 2012 |
not rated yet |
0
Novel test identifies patients most likely to benefit from ALK inhibition therapy
Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients ...
Medical research
Dec 12, 2012 |
not rated yet |
0
|
